Miru Smart Technologies and Mativ Collaborate to Develop Innovative Electrochromic Window Technology
9.10.2024 16:00:00 EEST | Business Wire | Press release
Mativ, global manufacturer of Argotec brand engineered polymer films, and Miru, a leading smart window technology developer, have announced a joint development agreement to commercialize a novel lamination interlayer for dynamic electrochromic windows (“eWindows”). This partnership will bring together technologies to simplify the manufacturing process and lower the cost of producing eWindows for glass fabricators and automakers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009187374/en/
“Partnering with Mativ, a company that shares our commitment to innovation, quality and sustainability, is a big step forward for the glass industry. Together, we will leverage our expertise and resources to develop an advanced eWindow technology that will offer breakthroughs in energy efficiency and comfort for the transportation and building sectors,” said Dr. Curtis Berlinguette, Chief Executive Officer of Miru.
"Powered by advanced Argotec TPU interlayer extrusions — an innovation born from Mativ’s materials expertise — this collaboration will accelerate the global adoption of dynamic eWindow technology. By utilizing Mativ’s Argotec solution, manufacturers worldwide can reduce energy consumption and lower their carbon footprint, driving meaningful environmental impact,” said Mativ President and Chief Executive Officer, Julie Schertell.
Smart window technology with on-demand tinting controls is revolutionizing the automotive industry by enhancing vehicle climate management and driver comfort. Miru’s eWindow technology is the only offering that meets growing consumer and regulatory demands for curved, neutral-color, low-haze, and energy-efficient glass. By dynamically adjusting tint levels, eWindows improve solar energy performance, reducing the need for air conditioning and heating within vehicles, and extending electric vehicle range substantially.
In the residential and commercial sectors, eWindows significantly increase overall building energy efficiency. Compared to conventional windows with low-emissivity coatings, eWindows can reduce energy usage by 20-40%, depending on geography and climate. The lamination interlayer is a versatile and durable thermoplastic polyurethane (TPU) film. Argotec is the world leader in extrusion of optical interlayer and edge seal films for a variety of glass lamination and glazing applications, with excellent durability, flexibility, chemical resistance, and clarity.
Mativ will be exhibiting a Miru sample eWindow at the International Glasstec trade show in Germany this October – visit Argotec in Hall 10, booth F74.
About Mativ
Mativ Holdings, Inc. is a global leader in specialty materials, solving our customers’ most complex challenges by engineering bold, innovative solutions that connect, protect and purify our world. Headquartered in Alpharetta, Georgia, we manufacture on three continents and generate sales in over 100 countries through our family of business-to-business and consumer product brands. The company’s two operating segments, Filtration & Advanced Materials and Sustainable & Adhesive Solutions, target premium applications across diversified and growing categories. Our broad portfolio of technologies combines polymers, fibers and resins to optimize the performance of our customers’ products across multiple stages of the value chain. Our leading positions are a testament to our best-in-class global manufacturing, supply chain and materials science capabilities. We drive innovation and enhance performance, finding potential in the impossible. To learn more, visit mativ.com.
About Argotec
Founded in 1988, Argotec is the global leader in engineered polymer films. Argotec provides unparalleled extrusion capability, capacity, and quality controls to support businesses across the globe. Argotec films are a critical component in a wide variety of industries, including automotive, aerospace, aviation, building & construction, medical, dental, consumer goods, graphics, renewable energy, safety & defense, and more. From surface and paint protection to smart glass and wound care, Argotec innovates everyday products. To learn more, visit argotec.com.
About Miru Smart Technologies
Miru Smart Technologies develops electrochromic windows ("eWindows") for the transportation and architectural sectors. Miru eWindows transform static glass into dynamic, responsive systems, disrupting industry standards with high performance, aesthetic and functionality. Miru is paving the way for the next generation of energy-efficient window technologies, with the vision to enhance the well-being of people and our planet. Learn more at mirucorp.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009187374/en/
Contacts
Brianne Vaskovardzic, brianne.vaskovardzic@mativ.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom